Cholangiocarcinoma Market Size & Share, by Product Type (Capecitabine, 5-Fluorouracil, Oxaliplatin, Gemcitabine, Cisplatin); Cancer Type (Intrahepatic Cholangiocarcinoma, Extrahepatic Cholangiocarcinoma); Therapy Type (Targeted Drug Therapy, Chemotherapy, Immunotherapy); Route of Administration (Oral, Subcutaneous, Intravenous); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5383
  • Published Date: Nov 20, 2023
  • Report Format: PDF, PPT

Companies Dominating the Cholangiocarcinoma Market

    • Verismo Therapeutics, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Eli Lilly and Company
    • AstraZeneca plc
    • Merck Sharp & Dohme LLC.
    • Basilea Pharmaceutica Ltd.
    • Incyte Corporation
    • Agios Pharmaceuticals Inc.
    • Specialised Therapeutics Asia Pte Ltd (ST)
    • PlantPraxis Biotecnologia
    • Dr. Reddy’s Laboratories Ltd.

Browse Key Market Insights with Data Illustration:


In The News

  • Verismo Therapeutics, a clinical-stage CAR T company and pioneer of the novel KIR-CAR platform technology, announced that it had received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SynKIR-110, an investigational new drug administered intravenously for the treatment of mesothelin-expressing mesothelioma, cholangiocarcinoma, and ovarian cancer.
  • AstraZeneca, a global pharmaceutical company, announced that Imfinzi (durvalumab), a human monoclonal antibody that binds to the PD-L1 protein, had been approved in the U.S. by the FDA for the treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with chemotherapy (gemcitabine plus cisplatin).

Author Credits:  Radhika Gupta, Shivam Bhutani

  • Report ID: 5383
  • Published Date: Nov 20, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The increasing Research & development and rising awareness about cholangiocarcinoma are the major factors driving the growth of the cholangiocarcinoma market.

The market size of cholangiocarcinoma is anticipated to attain a CAGR of 4% over the forecast period, i.e., 2024-2036.

The major players in the market are Eli Lilly and Company, AstraZeneca, Merck Sharp & Dohme Corp, Basilea Pharmaceutica, Incyte Corporation, Agios Pharmaceuticals, Specialised Therapeutics, PlantPraxis Biotecnologia, Dr. Reddy’s Laboratories, and others.

The retail pharmacy segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Inquiry Before Buying Request Free Sample

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying